Distribution of p values (116 QoL results from 30 trials). Note: The 116 QoL results come from 89 quantitative results and 27 reported as p values alone.
We are thrilled to unveil our latest review, delving deep into the evidence surrounding the impact of Disease-Modifying Therapies (DMTs) on the quality of life for individuals battling Multiple Sclerosis (MS).
Key findings:
- We analyzed 38 trials spanning from 1999 to 2023, involving over 23,000 participants.
- DMTs have the potential to significantly improve quality of life
- However, there seems to be no generally accepted standard for assessing disease-specific QoL in PwMS, and rarely is this end point in the focus of DMT-evaluating trials.
Join us in spreading awareness about the critical importance of quality of life in MS care. Together, let's advocate for better-designed trials that reflect the needs of patients.
Read full article: Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis
